- Deputy ACS R&D, Veterans Administration, Pittsburgh
Dr. Cambi is a Board-Certified Neurologist and a clinical investigator. Her clinical practice is focused on Movement Disorders and Neurogenetics. She has conducted several clinical trials on disease modifying agents for Parkinson Disease and has been a member of consortia on gene studies in Movement disorders and rare neurological diseases. Her laboratory-based research program has focused on several aspects of oligodendrocyte cell biology and myelination, ranging from transcriptional and post-transcriptional regulation of myelin gene expression and the impact of clinically relevant mutations on cell biology and myelin/axon biology in genetically modified mouse models. A main focus of her current research is to investigate how oligodendrocyte and myelin contribute to recovery and repair from traumatic injuries and neurodegeneration. Current studies are focused on the role of FUS, a DNA/RNA binding protein involved in transcriptional and post-transcriptional control of gene expression, in regulating myelination in development and in brain computer interface device performance in collaboration with Dr. Kozai. (Department of Bioengineering)
Education & Training
- Fellow, Shriver Center/MGH, Neuroscience
- Resident, Thomas Jefferson University, Neurology
- Intern, Medical College of Wisconsin, Medicine
- PhD, Universita di Firenze, Italy, Neuroscience
- MD, Universita di Firenze, Italy, Medicine
Specialized Areas of Clinical, Research and/or Educational Interests
- Clinical: Movement Disorders diagnosis and treatment; Neurogenetics
- Research: Myelin and oligodendrocyte biology in brain development and repair in traumatic injuries; molecular mechanisms of axon-glia interactions and their role in traumatic injuries and neurodegeneration
- Boards of Neurology and Psychiatry
Professional Organization Membership
- American Academy of Neurology
- Society for Neuroscience
- Nominated American Neurological Association
- American Society for Neurochemistry
- Parkinson Study Group
Honors & Awards
- Nominated, Best Doctors in America
Selected Recent Publications
Xing B, Brink LE, Maers K, Sullivan ML, Bodnar RJ, Stolz DB, Cambi F. Conditional depletion of GSK3b protects oligodendrocytes from apoptosis and lessens demyelination in the acute cuprizone model. Glia. 2018 Sep;66(9):1999-2012. doi: 10.1002/glia.23453. Epub 2018 May 15. PMID: 29761559.
Wellman SM, Cambi F, Kozai TD. The role of oligodendrocytes and their progenitors on neural interface technology: A novel perspective on tissue regeneration and repair. Biomaterials. 2018 Nov;183:200-217. doi: 10.1016/j.biomaterials.2018.08.046. Epub 2018 Aug 22. PMID: 30172245; PMCID: PMC6469877.
Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926. PMID: 30745444; PMCID: PMC6382364.
Guzman KM, Brink LE, Rodriguez-Bey G, Bodnar RJ, Kuang L, Xing B, Sullivan M, Park HJ, Koppes E, Zhu H, Padiath Q, Cambi F. Conditional depletion of Fus in oligodendrocytes leads to motor hyperactivity and increased myelin deposition associated with Akt and cholesterol activation. Glia. 2020 Oct;68(10):2040-2056. doi: 10.1002/glia.23825. Epub 2020 Mar 18. PMID: 32187401; PMCID: PMC7772959.
Wellman SM, Guzman K, Stieger KC, Brink LE, Sridhar S, Dubaniewicz MT, Li L, Cambi F, Kozai TDY. Cuprizone-induced oligodendrocyte loss and demyelination impairs recording performance of chronically implanted neural interfaces. Biomaterials. 2020 May;239:119842. doi: 10.1016/j.biomaterials.2020.119842. Epub 2020 Feb 6. PMID: 32065972; PMCID: PMC7540937.